Boston Scientific: The Beat-and-Cut Two-Step, Now in Its Second Encore

# Boston Scientific: The Beat-and-Cut Two-Step, Now in Its Second Encore

Here's a fun trick if you want to keep a stock cheap while still printing good numbers: beat every estimate on the top and bottom line, then tell everyone your full-year guidance is worse than you thought last quarter. Boston Scientific has now pulled this off twice in a row, and Wall Street still can't decide whether that's prudence or a slow-motion confession.

Let's start with what actually happened. On July 29, BSX put up Q2 2026 net sales of $5.442 billion — 7.5% reported growth, 7.0% organic, both ahead of what management had guided and what analysts modeled. Adjusted EPS came in at $0.86 versus $0.83 consensus, up 15% year-over-year. By the numbers alone, that's a company executing well. Roughly three-quarters of the portfolio is still growing at 6% or better. This is not a broken business.

And yet — for the second consecutive quarter — management trimmed the full-year outlook. FY2026 net sales growth is now pegged at 5.5% to 6.5%, down from April's 7% to 8.5% range. Organic growth got squeezed to 5%–6%. Adjusted EPS guidance landed at $3.28–$3.32, below the Street's $3.36. The culprits are the same two names that showed up last quarter: WATCHMAN and electrophysiology, with a side of Urology softness for good measure.

That's the part that should actually bother you. WATCHMAN and EP weren't supposed to be the problem children — they were the growth engines. WATCHMAN just posted genuinely strong clinical news: the CHAMPION-AF trial hit all its endpoints, showing WATCHMAN FLX beats blood thinners on bleeding protection. The market's response? The stock dropped about 1.4% on the news — a textbook sell-the-news reaction that tells you commercial reality is currently overpowering clinical validation. Meanwhile in EP, management openly copped to competitive share losses, in a segment BSX had been selling investors as its next multi-year growth story. When your two flagship franchises stumble in the same quarter, "one-off headwind" starts to sound like wishful framing.

Here's where it gets interesting, though, because the stock's setup doesn't match the gloom of the headline. Forward P/E sits around 14.3x — cheap relative to BSX's historical premium multiple, and cheap for a medtech name still growing organic revenue north of 5%. The Street's 44-analyst consensus target is $66.50, with a bull case stretching to $100, against a stock trading around $51 as of August 11. Even the bears aren't calling for a collapse — their downside case is $50, basically where the stock already sat. That's a strange spread for a name that just cut guidance twice running: the market is pricing in disappointment, but the analyst community isn't pricing in disaster.

Technically, the picture is a little muddled depending on which snapshot you trust — one read had RSI pinned at an overbought 87 on August 11, another has it closer to a more modest 67, sitting above both the 20-day ($49.19) and 50-day ($47.30) moving averages. Translation: momentum has been running hot into a fundamental story that's cooling. That combination — technical enthusiasm meeting guidance fatigue — is exactly the kind of setup that produces a chop rather than a clean trend, at least until the next data point arrives.

And the next real data point is Q3 earnings, expected in late October. That report is the actual test. If WATCHMAN commercial trends and EP share losses show even early signs of stabilizing, this becomes a classic "conservative management, cheap multiple, buy the guide-down" story. If they don't, the market will start pricing in management's own admission that the real turnaround — the "differentiated financial performance" they're promising — doesn't show up until 2028. That's a long time to ask investors to be patient on faith and a restructuring slide deck.

My take: this is a fundamentally sound company trading at a discounted multiple because two of its most-hyped franchises hit a wall at the same time, and management still hasn't proven it has fully bottomed the damage. That's not a reason to run — the balance sheet, cash flow, and breadth of the portfolio argue against panic. But it is a reason to treat every quarter between now and 2028 as a checkpoint, not a formality. Own it if you believe WATCHMAN and EP stabilize before Q3 turns into a third guidance cut. Just don't confuse a cheap stock with a resolved story — those are two very different things, and BSX is currently only offering you one of them.